B&L PureVision
This article was originally published in The Gray Sheet
Executive Summary
Washington D.C. federal appeals court declines to stay injunction against sales of the Bausch & Lomb extended-wear contact lens after a lower court's patent infringement ruling. The appeals process could take six-to-18 months, B&L says. As a result, the firm will move its PureVision manufacturing facilities to Ireland to ensure a continued supply to customers in Europe and Asia. A Delaware federal court found on June 26 that the device infringes a patent owned by CIBA Vision unit Wesley Jessen, blocking U.S. sales and production (11"The Gray Sheet" July 29, 2002, p. 17). B&L expects the decision will cost it $10 mil. in sales and $0.12-0.15 in earnings per share for the second half of 2002...
You may also be interested in...
Ciba Settles Cooper Lens Dispute; New CEO Brings Global Marketing Fluency
CooperVision will continue to sell its cosmetic contact lenses worldwide under an agreement with Ciba Vision that allows the firm to license Ciba colored contact lens patents in return for product royalties
B&L Awaits PureVision Court Decision; Restructuring Plan Cuts 450 Jobs
Bausch & Lomb does not expect a significant impact on sales of its PureVision extended-wear contact lenses abroad regardless of whether a federal court of appeals grants the firm a stay of an injunction on U.S. sales of the product line
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.